A Dose Response Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to Methotrexate
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Feb 2018
At a glance
- Drugs E 6011 (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Eisai Co Ltd
- 07 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 23 Nov 2016 Planned primary completion date changed from 1 Feb 2020 to 1 Mar 2018.